Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.16 CHF | -0.78% | -0.15% | +9.77% |
06:01am | Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment | MT |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.77% | 208B | |
+37.74% | 723B | |
+32.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.60% | 244B | |
-5.15% | 205B | |
+7.43% | 166B | |
+2.81% | 168B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Chinook Therapeutics' $3.5 Billion Buyout by Novartis Appreciates Value of Emerging Renal Pipeline, Oppenheimer Says